EUVIMEDDescoperă EUVIMED
Crossref

Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy

Yongsheng Zheng iD, Chong Sun, Yanyin Zhao, Quanhua Meng, Jianian Hu, Kai Qiao, Jian Sun, Jianying Xi, Sushan Luo, Jiahong Lu, Chongbo Zhao, Jie Lin

Journal of the Peripheral Nervous System · 2024

DOI: 10.1111/jns.12653 ↗

At a glance

Journal article in Journal of the Peripheral Nervous System, 2024. Written by Yongsheng Zheng and 11 co-authors. Institution: Department of Neurology, Huashan Hospital Fudan University, Shanghai, China. Major MEDLINE topics: Rituximab, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunologic Factors. Cited 10 times so far (Crossref); 27 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Objective

To evaluate the efficacy and safety of a low‐dose, long‐term rituximab regimen in the treatment of idiopathic CIDP.

Methods

This study included 15 CIDP patients treated with rituximab. Patients were administered 600 mg of rituximab intravenously every 6 months. Baseline evaluation was conducted before the initiation of rituximab treatment and subsequent evaluations were conducted 6 months after each rituximab infusion at on‐site visits. Clinical improvement was objectively determined by improvement of scale score at least decrease ≥1 INCAT or mRS or increase ≥4 MRC or ≥8 cI‐RODS after each infusion compared to baseline evaluation.

Results

Fifteen CIDP patients were included and 10 of them were typical CIDP and five were distal CIDP. Nine in 15 (60%) patients after first infusion and three in six (50%) patients after second infusion exhibited significant clinical improvement compared to baseline evaluation. Additionally, rituximab facilitated a reduction or cessation of other medications in 73% of patients at last visit. The safety profile was favorable, with no reported adverse events.

Conclusion

Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low‐dose, long‐term regimen.

Subjects

MeSH terms (MEDLINE)

RituximabPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunologic FactorsHumansMaleMiddle AgedFemaleAgedAdultTreatment Outcome

Author keywords

chronic inflammatory demyelinating polyneuropathylong termlow‐doserituximabtreatment

Substances

RituximabImmunologic Factors

Authors and institutions

  • Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
  • National Center for Neurological Disorders (NCND), Shanghai, China.
  • Huashan Rare Disease Center, Huashan Hospital Fudan University, Shanghai, China.
  • Department of Neurology, Deyang People's Hospital, Deyang, China.

ORCID profiles: Yongsheng Zheng

Cite

APA

Zheng, Y., Sun, C., Zhao, Y., Meng, Q., Hu, J., Qiao, K., Sun, J., Xi, J., Luo, S., Lu, J., Zhao, C., & Lin, J. (2024). Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12653

Vancouver

Zheng Y, Sun C, Zhao Y, Meng Q, Hu J, Qiao K, et al. Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12653

BibTeX
@article{Zheng2024,
  author = {Zheng, Yongsheng and Sun, Chong and Zhao, Yanyin and Meng, Quanhua and Hu, Jianian and Qiao, Kai and Sun, Jian and Xi, Jianying and Luo, Sushan and Lu, Jiahong and Zhao, Chongbo and Lin, Jie},
  title = {Long‐term and low‐dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  doi = {10.1111/jns.12653}
}
Start for free →